Alexandria Hammond
Stock Analyst at B of A Securities
(1.74)
# 3,206
Out of 4,898 analysts
16
Total ratings
54.55%
Success rate
-3.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $52.72 | +21.40% | 4 | May 27, 2025 | |
REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $570.59 | +101.55% | 1 | Nov 15, 2024 | |
PFE Pfizer | Initiates: Underperform | $25 | $25.35 | -1.38% | 1 | Nov 15, 2024 | |
MRNA Moderna | Initiates: Underperform | $40 | $32.87 | +21.69% | 1 | Nov 15, 2024 | |
MRK Merck & Co. | Initiates: Peer Perform | n/a | $83.67 | - | 1 | Nov 15, 2024 | |
LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $799.34 | +25.10% | 1 | Nov 15, 2024 | |
JNJ Johnson & Johnson | Initiates: Outperform | $190 | $156.82 | +21.16% | 1 | Nov 15, 2024 | |
GILD Gilead Sciences | Initiates: Outperform | $110 | $112.09 | -1.86% | 1 | Nov 15, 2024 | |
BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $47.34 | - | 1 | Nov 15, 2024 | |
BIIB Biogen | Initiates: Peer Perform | n/a | $133.11 | - | 1 | Nov 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $191.52 | +7.04% | 1 | Nov 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $318.86 | -52.96% | 1 | Apr 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $11.12 | +169.78% | 1 | Apr 22, 2024 |
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $52.72
Upside: +21.40%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $570.59
Upside: +101.55%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $25.35
Upside: -1.38%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $32.87
Upside: +21.69%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $83.67
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $799.34
Upside: +25.10%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $156.82
Upside: +21.16%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $112.09
Upside: -1.86%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $47.34
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $133.11
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $191.52
Upside: +7.04%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $318.86
Upside: -52.96%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $11.12
Upside: +169.78%